Duke Inst links with pharma majors on care for people with type 2 diabetes and CD

The Duke Clinical Research Institute (DCRI) is leading a new clinical study to optimize care for people with type 2 diabetes and cardiovascular disease through evaluation of a multidisciplinary approach at cardiology clinics across the USA.

The research program, COORDINATE-Diabetes (COOrdinating CaRDIology CliNics RAndomized Trial of Interventions to Improve OutcomEs), will be funded by family-owned German drug major Boehringer Ingelheim and its US partner on diabetes, Eli Lilly (NYSE: LLY).

“The public health impact of type 2 diabetes and cardiovascular disease in the US is immense,” said Dr Christopher Granger, professor of medicine in the Division of Cardiology at Duke University and lead researcher for COORDINATE-Diabetes. “While highly effective evidence-based treatments have been developed, these treatments are not consistently used, and thus preventable death and disability are occurring. Our goal with COORDINATE-Diabetes is to better understand the effectiveness of specific interventions at cardiology clinics to achieve best practices for improving patient health,” he explained.